Crossmark

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2022-005041

Published Online: 2022-07-05

Published Print: 2022-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Kwon, Minsuk

Kim, Gahyun

Kim, Ryul

Kim, Kyu-Tae

Kim, Seung Tae

Smith, Simon

Mortimer, Peter G S

Hong, Jung Yong

Loembé, Arsene-Bienvenu

Irurzun-Arana, Itziar

Koulai, Loumpiana

Kim, Kyoung-Mee https://orcid.org/0000-0002-1162-9205
Kang, Won Ki

Dean, Emma

Park, Woong-Yang

Lee, Jeeyun
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03780608 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
https://doi.org/10.1136/jitc-2022-005041
Funding

Funding for this research was provided by:

Sung Kyun Kwan University
License Information

License valid from 2022-07-05